Not long ago, in February this year in Berlin, the 16th international conference on new technologies and treatments for diabetes mellitus was held.
One of the main topics of discussion was continuous blood glucose monitoring (CGM).
Currently 8 million people worldwide are already using CGM systems, which is only 1.5% of the potential market, and this number is increasing every year.
Using this technology depends on its accessibility to the population.
Many countries are gradually including CGM in their diabetes benefit list.
This fact undoubtedly indicates a systematic increase in the demand for this technology.
CGM technology not only helps control diabetes, but can also be used to determine the risk of developing diabetes mellitus disease.
By collecting and analysing all informational statistics, CGM systems make it possible to predict the risk of diabetes with up to 80% probability.
In conclusion, there is a global recognition of the need for innovation in medicine, particularly in the treatment and control of diabetes mellitus.
Our MLC project is in a cutting-edge, sought-after niche whose developments could help millions of people around the world.
